A novel anti-VEGF165 monoclonal antibody-conjugated liposomal nanocarrier system: physical characterization and cellular uptake evaluation in vitro and in vivo.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2015-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.biopha.2014.11.025PMID 25661357
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of VEGF, P53 and telomerase on angiogenesis of gastric carcinoma tissue.

  2014cited by this paper
• Development of monoclonal antibodies to pre-haptoglobin 2 and their use in an enzyme-linked immunosorbent assay (ELISA).

  2014cited by this paper
• Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment.

  2014cited by this paper
• Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.

  2013cited by this paper
• Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.

  2012cited by this paper
• Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.

  2012cited by this paper
• Design of a Pep-1 peptide-modified liposomal nanocarrier system for intracellular drug delivery: Conformational characterization and cellular uptake evaluation

  2011cited by this paper
• Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor.

  2011cited by this paper
• Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential.

  2010cited by this paper
• Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.

  2010cited by this paper
• Targeting EGFR-overexpressing tumor cells using Cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide.

  2010cited by this paper
• Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding.

  2010cited by this paper
• Understanding and managing the possible adverse effects associated with bevacizumab.

  2009cited by this paper
• Novel peptide ligand directs liposomes toward EGF‐R high‐expressing cancer cells in vitro and in vivo

  2009cited by this paper
• Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.

  2009cited by this paper
• Morphology, binding behavior and MR-properties of paramagnetic collagen-binding liposomes.

  2009cited by this paper
• Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome.

  2007cited by this paper
• Protein-liposome conjugates using cysteine-lipids and native chemical ligation.

  2007cited by this paper
• Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205.

  2007cited by this paper
• Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.

  2007cited by this paper
• Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.

  2005cited by this paper
• Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy.

  2005cited by this paper
• Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes

  2004cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• Use of the Post-Insertion Technique to Insert Peptide Ligands into Pre-Formed Stealth Liposomes with Retention of Binding Activity and Cytotoxicity

  2002cited by this paper
• Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

  2002cited by this paper
• Tumor targeting using anti-her2 immunoliposomes.

  2001cited by this paper
• Assay of a seric human hexapeptide (HWESAS) using a monoclonal antibody and ELISA.

  2000cited by this paper
• Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin.

  2000cited by this paper
• The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs.

  1999cited by this paper
• In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.

  1998cited by this paper
• An ELISA to determine the biodistribution of human monoclonal antibody in tumor-xenografted SCID mice.

  1998cited by this paper
• Brain drug delivery of small molecules using immunoliposomes.

  1996cited by this paper
• Development of anti-p185HER2 immunoliposomes for cancer therapy.

  1995cited by this paper
• Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft.

  1994cited by this paper
• Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

  1994cited by this paper
• Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

  1991cited by this paper
• Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

  1990cited by this paper
• Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

  1988cited by this paper

• Leveraging microbial natural products for pharmaceutical innovation: a vision of inspiration and future prospects.

  2025cites this paper
• PEGylated pH-Responsive Liposomes for Enhancing the Intracellular Uptake and Cytotoxicity of Paclitaxel in MCF-7 Breast Cancer Cells

  2024cites this paper
• Topical delivery of Anti-VEGF nanomedicines for treating psoriasis

  2023cites this paper
• Chlorin e6 (Ce6)-loaded plaque-specific liposome with enhanced photodynamic therapy effect for atherosclerosis treatment.

  2023cites this paper
• Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies

  2022cites this paper
• Unfolding the Potency of Adenosine in Targeting Triple Negative Breast Cancer via Paclitaxel-Incorporated pH-Responsive Stealth Liposomes.

  2022cites this paper
• An Iron(III)-Based Metal-Organic Gel-Catalyzed Dual Electrochemiluminescence System for Cytosensing and In Situ Evaluation of the VEGF165 Subtype.

  2022cites this paper
• Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy.

  2021cites this paper
• A review on liposome-based therapeutic approaches against malignant melanoma.

  2021cites this paper
• Preparation, Characterization, and in vivo Evaluation of NK4-Conjugated Hydroxycamptothecin-Loaded Liposomes

  2020cites this paper
• Multiscale live imaging using Förster Resonance Energy Transfer (FRET) for evaluating the biological behavior of nanoparticles as drug carriers.

  2020cites this paper
• Phospholipase-Cγ1 Signaling Protein Down-Regulation by Oligoclonal-VHHs based Immuno-Liposome: A Potent Metastasis Deterrent in HER2 Positive Breast Cancer Cells

  2019cites this paper
• Advances in targeted drug delivery of cell-penetrating peptide-modified liposomes

  2019cites this paper
• Drug delivery targets and systems for targeted treatment of rheumatoid arthritis

  2018cites this paper
• Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.

  2017cites this paper
• Surface modification of lipid-based nanocarriers for cancer cell-specific drug targeting

  2017cites this paper
• Oestrone‐targeted liposomes for mitoxantrone delivery via oestrogen receptor – synthesis, physicochemical characterization and in‐vitro evaluation

  2017cites this paper
• Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO2@LDH for anti-neuroblastoma therapy.

  2017cites this paper
• Nanomaterial scaffolds to regenerate musculoskeletal tissue: signals from within for neovessel formation.

  2017cites this paper
• Anti-EGFR immunonanoparticles containing IL12 and salmosin genes for targeted cancer gene therapy.

  2016cites this paper
• A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours

  2016cites this paper
• Two Novel Heparin-binding Vascular Endothelial Growth Factor Splices, L-VEGF144 and L-VEGF138, are Expressed in Human Glioblastoma Cells.

  2016cites this paper
• Decoration of pH-sensitive copolymer micelles with tumor-specific peptide for enhanced cellular uptake of doxorubicin

  2016cites this paper
• Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.

  2015cites this paper
• Delivery systems for biopharmaceuticals. Part II: Liposomes, Micelles, Microemulsions and Dendrimers.

  2015cites this paper
• Review peptide‐targeted liposomes for selective drug delivery: Advantages and problematic issues

  2015cites this paper